What You Should Know:
– Repurpose.AI, has partnered with Scripps Research to
discover drug candidates that may be repurposed to treat COVID-19.
– The partnership will leverage Repurpose.AI’s ActivPred
AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic
digital chemistry engine, to discover drug candidates to treat COVID-19.
Scripps Research is
teaming up with Repurpose.AI, an AI
drug discovery company to develop COVID-19 therapeutics. The partnership will
leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug,
target, and disease agnostic digital chemistry engine, to discover drug
candidates to treat COVID-19. Previously, the company has successfully utilized
the platform to discover REP-001, REP-002, and REP-003 – three Phase II/III
ready small molecule assets for the treatment of gastric, neurological, and
weight disorders, respectively.
Partnership Details
Scripps Research scientists together with Calibr,
its drug development division, will leverage its COVID-19
screening models and commitment to drug repurposing as part of the partnership.
Calibr previously established the ReFRAME collection, the world’s leading
collection of known drugs, comprising over 14,000 compounds that have been
approved by the FDA for other diseases or have been extensively tested for
human safety, which it is bringing to bear on the current pandemic. The
collaborative work with Repurpose.AI will augment this effort by characterizing
compounds not identified to date using conventional repurposed drug screening
approaches.
“We could not be more excited about our partnership with Scripps Research and Calibr. Like Repurpose.AI, Calibr is committed to ending the scourge of the global COVID-19 pandemic. Our goal is to move therapeutics from the computer to the clinic in a fraction of the time typically required to discover and bring new drugs to market and alleviate the suffering of patients afflicted by COVID-19. Creating therapeutics to treat COVID-19 also allows the global community to go back to work and for children to go back to school. Repurpose.AI and Calibr are committed to doing our part to ensure that happens sooner rather than later,” said Dr. Daniel Haders II, Ph.D., Executive Chairman at Repurpose.AI.
AI-Driven Drug Discovery
Repurpose.AI, a Nex Cubed digital health
portfolio company, has harnessed the predictive prowess of artificial
intelligence and machine learning with its ActivPred AI Drug Discovery Platform
to discover drugs that may be repurposed to serve as therapeutics to treat
patients suffering from COVID-19. The drugs that Repurpose.AI discovers for
COVID-19 can enter clinical trials in as little as several months.
Repurpose.AI’s Drug Library
Repurpose.AI’s Drug Library is comprised of approximately
4,000 drug compounds that have been approved for commercial use by the U.S.
FDA, or similar agencies, and 20,000+ drug compounds that are known to have
successfully navigated a Phase I (human safety) clinical trial. All drugs have
a full pre-clinical program, an existing or legacy supply chain, and are known
to be safe and well-tolerated in humans.
